Sorafenib is a multikinase inhibitor with a dual mechanism of action against tumor cell proliferation and tumor angiogenesis through its action on the Raf/MEK/ERK pathway and the VEGF and PDGF receptor families [64,65]. The gene discussed is RAF1; the disease is neoplasm.